International Experts Advance Clinical Adoption of Islet Cell Therapies at Breakthrough T1D HQ
Islet cell therapies for type 1 diabetes (T1D) replace destroyed insulin-producing beta cells with functional cells that allow the body to make insulin again. To ensure there are enough islet cells for everyone with T1D who wants them, Breakthrough T1D is prioritizing manufactured cell therapies, which can be made in large quantities in a laboratory, […]
Two Highly Engaged Volunteer Leaders Elected to Head Breakthrough T1D’s International Board of Directors
Karen Shishino Jordan, a long-time volunteer leader in the greater California Bay area, will serve as Breakthrough T1D (formerly JDRF) International Board of Directors (IBOD) Chair, succeeding current Chair Lisa Fishbone Wallack. Carlton McMillan, also a dedicated volunteer leader in the greater California Bay area, will serve as Vice Chair, succeeding current Vice Chair Matt Varey. Karen’s and Carlton’s terms as Chair and Vice Chair, respectively, begin Wednesday, July 1, 2026. Breakthrough […]
Remembering Marilyn and Gerald Fishbone
For more than 50 years, Marilyn and Gerald Fishbone were pillars in the T1D community, dedicating their lives to helping advance innovative research.
ATTD 2026 Days 3 and 4 – Breakthroughs Transforming T1D
Breakthrough T1D is back from Barcelona! The final two days of ATTD were jam-packed with more incredible updates across all areas of our mission. Breakthrough T1D staff chaired and participated in many sessions—including Breakthrough T1D Senior Vice President of Research, Esther Latres, Ph.D.; Vice President of Medical Affairs Anastasia Albanese O’Neill, Ph.D., APRN, CDCES; Senior […]
ATTD 2026 Days 1 and 2 – Breakthroughs Transforming T1D
Greetings from Barcelona, Spain! From March 11–14, 2026, the world’s leading type 1 diabetes (T1D) researchers, healthcare professionals, and industry partners gathered to share groundbreaking advances in T1D science—and Breakthrough T1D–supported work (and staff) were front and center. Below is everything you need to know from the first two days of this remarkable conference, including […]
“Do good, feel good”: Alecia Wesner’s T1D clinical trial journey
This article was written by Alecia Wesner (pictured above, right), a Participant Advisory Council (PAC) member, a Clinical Trial Education Volunteer, and long-time Breakthrough T1D supporter. Alecia’s story details her lived experiences with type 1 diabetes, participation in clinical trials, and her journey to joining the PAC. The views expressed by the author are her […]
Cardiovascular disease and T1D: Advancing breakthroughs in Europe and beyond
What’s happening? Today, Breakthrough T1D co-hosted an event with leading international diabetes organizations to discuss cardiovascular disease (CVD) and type 1 diabetes (T1D)—where we are, challenges that remain, and how we can work together in Europe and beyond to address this need for the T1D community. The focus of the event: Doing more for CVD […]
Highlights from the 2025 ISPAD conference
Bonjour from Montreal, Canada, where the latest and greatest in type 1 diabetes (T1D) research was presented at the International Society for Pediatric and Adolescent Diabetes (ISPAD) 51st Annual Conference. ISPAD is a yearly highlight of the T1D conference calendar, and this year was no exception. Scientists, clinicians, researchers, industry members, people with diabetes, and […]
Ten years of impact: A closer look at Breakthrough T1D’s training awards
To drive our mission forward, Breakthrough T1D financially supports type 1 diabetes (T1D) research through training awards and grants to academic scientists or clinicians, investments in promising companies, conference support, and more. Here, we take a deeper dive specifically into our training awards offered to early-stage researchers to understand the impact and outcomes that these […]
A new Breakthrough T1D publication is paving the way for beta cell replacement therapies
Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.